search
Back to results

Postconditioning in Primary PCI and Direct Stenting

Primary Purpose

Myocardial Infarction

Status
Unknown status
Phase
Not Applicable
Locations
Israel
Study Type
Interventional
Intervention
Postconditioning
Sponsored by
Sheba Medical Center
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Myocardial Infarction focused on measuring Myocardial Infarction, Primary PCI, Postconditioning, MRI

Eligibility Criteria

21 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Patient is > 21 years of age and provides informed consent. Evidence of AMI as indicated by signs and symptoms. Diagnosis of ST-segment elevation AMI will be based on chest pain for >30 minutes and ST-segment elevation of >1mV in 2 limb lead or >2mV in 2 anterior leads contiguous leads on the 12-lead ECG. Eligible to undergo primary PCI. Symptom duration is < 6 hours prior to primary PCI. Angiographic: The target lesion in the infarct related artery (IRA) should be occluded (TIMI). Angiographic: The target lesion in the proximal or middle segment of a native major coronary artery (LAD, RCA or dominant CX). Angiographic: The target lesion should be suitable for PTCA or stenting. Angiographic: The IRA occlusion will be successfully opened by stenting with TIMI 2-3 Exclusion Criteria: Unwillingness to participate. Prior Acute MI Cardiac arrest or Killip score III-IV Women with known pregnancy. Active significant bleeding. Known allergy for aspirin, ticlopidine and clopidogrel, or heparin. Chronic renal failure with creatinine > 2 mg/dl Other medical illness associated with limited life expectancy or that may cause the patient to be non-compliant with the protocol. Current participation in other trials using investigational drugs or devices. Contraindications to MRI including: arrythmias, cardiac pacer, brain aneurysm clips, cochlear implants, nerve stimulator.

Sites / Locations

  • Sheba Medical Center

Outcomes

Primary Outcome Measures

ST segment resolution.
Segmental wall motion score, resolution of edema and wall thickness by echocardiography.
Infarct size estimation by cardiac enzymes and cardiac MRI.

Secondary Outcome Measures

Composite endpoint of Major Adverse Cardiac Events (MACE) at 30 and 90 days

Full Information

First Posted
July 11, 2006
Last Updated
July 11, 2006
Sponsor
Sheba Medical Center
search

1. Study Identification

Unique Protocol Identification Number
NCT00351247
Brief Title
Postconditioning in Primary PCI and Direct Stenting
Official Title
Clinical and MRI Evaluation of 2 Vs 4 Cycles of Postconditioning During Primary PCI With Direct Stenting
Study Type
Interventional

2. Study Status

Record Verification Date
July 2006
Overall Recruitment Status
Unknown status
Study Start Date
July 2006 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
May 2007 (undefined)

3. Sponsor/Collaborators

Name of the Sponsor
Sheba Medical Center

4. Oversight

5. Study Description

Brief Summary
To determine the safety and efficacy of 2 vs 4 cycles of postconditioning method during primary PCI and direct stenting in acute MI, and to compared to primary PCI and direct stenting without the postconditioning.
Detailed Description
Sample size: 45 subjects Site Locations: Sheba medical center Patients: Patients presenting with an acute MI with onset of symptoms  6h, and planned to undergo primary PCI will be included. The target lesion should be located in the proximal or middle segment of a main native coronary artery, and should be suitable for percutaneous intervention. Primary Objective: To determine the safety and efficacy of 2 vs 4 cycles of postconditioning method during primary PCI and direct stenting in acute MI, and to compared to primary PCI and direct stenting without the postconditioning. Primary Endpoint: ST segment resolution. Segmental wall motion score, resolution of edema and wall thickness by echocardiography. Infarct size estimation by cardiac enzymes and cardiac MRI. Secondary endpoints: Composite endpoint of Major Adverse Cardiac Events (MACE) at 30 and 90 days Methods: ECG at baseline, immediately after procedure, 90 and 180 minutes after the procedure and 6-24 hours after intervention. Core laboratory angiography measurements of TIMI flow, corrected TIMI Frame count, myocardial blush score and left ventricular angiography. Myocardial enzymes measurements: every 4 hours in the first 24 hours and every 6 hours in the following 48 hours. Left ventricular ejection fraction and wall motion score determined by echocardiography. Cardiac MRI estimation of infarct size. • Clinical follow-up at 30 and 90 days post procedure. Follow-up: Follow up at 30 days: Clinical. Clinical Follow up & Cardiac MRI at 90 days.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Myocardial Infarction
Keywords
Myocardial Infarction, Primary PCI, Postconditioning, MRI

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
45 (false)

8. Arms, Groups, and Interventions

Intervention Type
Procedure
Intervention Name(s)
Postconditioning
Primary Outcome Measure Information:
Title
ST segment resolution.
Title
Segmental wall motion score, resolution of edema and wall thickness by echocardiography.
Title
Infarct size estimation by cardiac enzymes and cardiac MRI.
Secondary Outcome Measure Information:
Title
Composite endpoint of Major Adverse Cardiac Events (MACE) at 30 and 90 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
21 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patient is > 21 years of age and provides informed consent. Evidence of AMI as indicated by signs and symptoms. Diagnosis of ST-segment elevation AMI will be based on chest pain for >30 minutes and ST-segment elevation of >1mV in 2 limb lead or >2mV in 2 anterior leads contiguous leads on the 12-lead ECG. Eligible to undergo primary PCI. Symptom duration is < 6 hours prior to primary PCI. Angiographic: The target lesion in the infarct related artery (IRA) should be occluded (TIMI). Angiographic: The target lesion in the proximal or middle segment of a native major coronary artery (LAD, RCA or dominant CX). Angiographic: The target lesion should be suitable for PTCA or stenting. Angiographic: The IRA occlusion will be successfully opened by stenting with TIMI 2-3 Exclusion Criteria: Unwillingness to participate. Prior Acute MI Cardiac arrest or Killip score III-IV Women with known pregnancy. Active significant bleeding. Known allergy for aspirin, ticlopidine and clopidogrel, or heparin. Chronic renal failure with creatinine > 2 mg/dl Other medical illness associated with limited life expectancy or that may cause the patient to be non-compliant with the protocol. Current participation in other trials using investigational drugs or devices. Contraindications to MRI including: arrythmias, cardiac pacer, brain aneurysm clips, cochlear implants, nerve stimulator.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Victor Guetta, MD
Phone
972-52-6667127
Email
victor.Guetta@health.sheba.gov.il
First Name & Middle Initial & Last Name or Official Title & Degree
Elad Maor, MD
Phone
972-52-3691613
Email
elad.maor@gmail.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Victor Guetta, MD
Organizational Affiliation
Sheba Medical Center
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Jonathan Leor, MD
Organizational Affiliation
Neufeld Cardiac Research Center
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Elad Maor, MD
Organizational Affiliation
Neufeld Cardiac Research Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Sheba Medical Center
City
Tel Hashomer
Country
Israel
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Victor Guetta, MD
Phone
972-52-6667127
Email
victor.Guetta@health.sheba.gov.il
First Name & Middle Initial & Last Name & Degree
Elad Maor, MD
Phone
972-52-3691613
Email
elad.maor@gmail.com

12. IPD Sharing Statement

Citations:
PubMed Identifier
16186417
Citation
Staat P, Rioufol G, Piot C, Cottin Y, Cung TT, L'Huillier I, Aupetit JF, Bonnefoy E, Finet G, Andre-Fouet X, Ovize M. Postconditioning the human heart. Circulation. 2005 Oct 4;112(14):2143-8. doi: 10.1161/CIRCULATIONAHA.105.558122. Epub 2005 Sep 26.
Results Reference
background
PubMed Identifier
12860564
Citation
Zhao ZQ, Corvera JS, Halkos ME, Kerendi F, Wang NP, Guyton RA, Vinten-Johansen J. Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning. Am J Physiol Heart Circ Physiol. 2003 Aug;285(2):H579-88. doi: 10.1152/ajpheart.01064.2002. Erratum In: Am J Physiol Heart Circ Physiol. 2004 Jan;286(1):H477.
Results Reference
background

Learn more about this trial

Postconditioning in Primary PCI and Direct Stenting

We'll reach out to this number within 24 hrs